Hikma Pharmaceuticals (GB:HIK) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Hikma Pharmaceuticals has decided to reappoint PricewaterhouseCoopers LLP as its external auditor starting in 2026, following a competitive audit tender process. As part of regulatory requirements, Hikma must rotate auditors every 20 years, and this decision awaits shareholder approval at the 2026 Annual General Meeting. Investors may find this continuity in auditing services a point of stability for the company’s financial oversight.
For further insights into GB:HIK stock, check out TipRanks’ Stock Analysis page.
